The has Dow bounced back after this morning drop
The Dow Jones Industrial Average (DJI) was initially dragged lower this morning by Boeing (BA) -- down on news of another fatal crash -- and Walgreens Boots Alliance (WBA), which is selling off after earnings. The Dow is now trading higher with the S&P 500 Index (SPX) and Nasdaq Composite (IXIC), with the latter two hitting record highs, as investors took last night's non-fatal Iranian ballistic missile attack against a U.S. military base in Iraq, to mean the worst is over between the two countries. The rise in stocks has sent February-dated gold futures, which have been on a tear recently, lower, down 1% at $1,557.80 an ounce, at last check.
Continue reading for more on today's market, including:
- Options bulls bombard Beyond Meat stock during breakout.
- RBC's bull note could help snap this biotech's losing streak.
- Plus, EA stock hits fresh high; the software stock that's doubled today; and GENE stock cools off.
Electronic Arts Inc. (NASDAQ:EA) is seeing an usual amount of bullish activity in the option pits today, with 16,000 call contracts exchanging hands so far -- six times the average intraday amount, and roughly eight times the number of puts. The most popular position, by far, is the weekly 1/10 108-strike call, which expires at the close this Friday, with contracts being bought to open here. The shares are up 0.6% to trade at $109.01, and just hit a 15-month high of $109.67 earlier.
Software maker ShiftPixy Inc (NASDAQ:PIXY) has more than doubled today, following an announcement that the company closed a contract assignment valued at $20 million, which is 60% of all of its contracted book of business. The firm plans on using the funding to achieve cash flow breakeven by the middle of 2020. The stock earlier hit a five-month high of $27.50 in response, and is now up 155% at $19.74, testing its footing atop its 180-day moving average for the first time since November 2018.
One of the worst performing stocks on the Nasdaq is
Genetic Technologies Limited (NASDAQ:GENE), which has shed 21.1% to trade at $3.56, just one day after the stock more than doubled on news the company's breast cancer test is set to launch in the U.S. While the stock has cooled today, it's still set for its second straight close atop its 320-day moving average, which hasn't happened since last May.